

## DESCRIPTION

<b>Species Reactivity</b>	Human
<b>Specificity</b>	Detects human Wnt-10b in direct ELISAs. In direct ELISAs, 100% cross-reactivity with recombinant mouse Wnt-10b is observed and no cross-reactivity with recombinant human Wnt-6 is observed.
<b>Source</b>	Monoclonal Mouse IgG <sub>2A</sub> Clone # 793116
<b>Purification</b>	Protein A or G purified from hybridoma culture supernatant
<b>Immunogen</b>	Chinese hamster ovary cell line CHO-derived recombinant human Wnt-10b Asn29-Lys389 Accession # O00744
<b>Formulation</b>	Lyophilized from a 0.2 µm filtered solution in PBS with Trehalose. See Certificate of Analysis for details. *Small pack size (-SP) is supplied as a 0.2 µm filtered solution in PBS.


## APPLICATIONS

**Please Note:** Optimal dilutions should be determined by each laboratory for each application. *General Protocols* are available in the *Technical Information* section on our website.

	<b>Recommended Concentration</b>	<b>Sample</b>
<b>Immunohistochemistry</b>	8-25 µg/mL	See Below

## DATA

### Immunohistochemistry



**Wnt-10b in Human Breast Cancer Tissue.** Wnt-10b was detected in immersion fixed paraffin-embedded sections of human breast cancer tissue using Mouse Anti-Human Wnt-10b Monoclonal Antibody (Catalog # MAB71961) at 15 µg/mL overnight at 4 °C. Before incubation with the primary antibody, tissue was subjected to heat-induced epitope retrieval using Antigen Retrieval Reagent-Basic (Catalog # CTS013). Tissue was stained using the Anti-Mouse HRP-DAB Cell & Tissue Staining Kit (brown; Catalog # CTS002) and counterstained with hematoxylin (blue). Specific staining was localized to cytoplasm of cancer cells. View our protocol for [Chromogenic IHC Staining of Paraffin-embedded Tissue Sections](#).

## PREPARATION AND STORAGE

<b>Reconstitution</b>	Sterile PBS to a final concentration of 0.5 mg/mL.
<b>Shipping</b>	The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. *Small pack size (-SP) is shipped with polar packs. Upon receipt, store it immediately at -20 to -70 °C
<b>Stability &amp; Storage</b>	<b>Use a manual defrost freezer and avoid repeated freeze-thaw cycles.</b> <ul style="list-style-type: none"> <li>● 12 months from date of receipt, -20 to -70 °C as supplied.</li> <li>● 1 month, 2 to 8 °C under sterile conditions after reconstitution.</li> <li>● 6 months, -20 to -70 °C under sterile conditions after reconstitution.</li> </ul>

## BACKGROUND

Wnt-10b (also known as Wnt-12) is a 42-44 kDa member of the Wnt family of secreted, highly conserved, cysteine-rich glycoproteins that play important roles in vertebrate pattern formation, cell fate decision, axon guidance, and tumor formation (1-3). Human Wnt-10b cDNA encodes a 389 amino acid (aa) precursor that contains a 28 aa signal sequence plus a 361 aa mature protein that contains two glycosylation sites, three potential phosphorylation sites, and a potential palmitoylation site (3, 4). Human Wnt-10b shares 97-99% aa identity with mouse, rat, equine, porcine, and canine Wnt-10b. Wnt-10b plays a critical role in maintaining mesenchymal stem cells and determining whether they differentiate to adipocytes or osteoblasts (5-7). Mouse Wnt-10b deletion produces age-dependent loss of bone mass due to defective production of osteoblasts, while transgenic over-expression increases postnatal osteoblast differentiation and inhibits adipocyte differentiation (5-7). Ectopic expression of Wnt-10b in an obesity and diabetes-prone background, such as the ob/ob mouse, inhibits obesity (8). In mouse skeletal muscle, Wnt-10b is expressed inversely with SREBP1c and increases insulin sensitivity (9). In humans, a missense polymorphism is responsible for a malformation of hands and feet, while a C256Y inactivating mutation is associated with severe early-onset obesity (10, 11). Wnt-10b is mainly produced by stem cells and pre-osteoblasts, but also by adult bone marrow CD8<sup>+</sup> T lymphocytes stimulated with parathyroid hormone (12). In some hepatocellular carcinomas, Wnt-10b can inhibit cancer cell growth, but in others, it can act synergistically with FGFs to stimulate cell growth (13). Several Wnts, including Wnt-10b, are expressed in both normal and/or malignant colon tissues (14).

## References:

1. Hardiman, G. *et al.* (1997) *Cytogenet. Cell Genet.* **77**:278.
2. Katoh, M. (2008) *Curr. Drug Targets* **9**:565.
3. Hausmann, G. *et al.* (2007) *Nat. Rev. Mol. Cell Biol.* **8**:331.
4. Swiss Prot Accession # O00744.
5. Stevens, J.R. *et al.* (2010) *J. Bone Miner. Res.* **25**:2138.
6. Bennett, C.N. *et al.* (2007) *J. Bone Miner. Res.* **22**:1924.
7. Bennett, C.N. *et al.* (2005) *Proc. Natl. Acad. Sci. USA* **102**:3324.
8. Wright, W.S. *et al.* (2007) *Diabetes* **56**:295.
9. Abiola, M. *et al.* (2009) *PLoS ONE* **4**:e8509.
10. Ugur, S.A. and A. Tolun (2008) *Hum. Mol. Genet.* **17**:2644.
11. Christodoulides, C. *et al.* (2006) *Diabetologia* **49**:678.
12. Terauchi, M. *et al.* (2009) *Cell Metab.* **10**:229.
13. Yoshikawa, H. *et al.* (2007) *Mol. Biol. Cell* **18**:4292.
14. Holcombe, R.F. *et al.* (2002) *J. Clin. Pathol. Mol. Pathol.* **55**:220.